Arvinas Inc (ARVN)

$12.30 +0.31 (2.59%)
Market Cap 770.05M
Revenue (ttm) 263.40M
Net Income (ttm) -198.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -75.51%
Debt to Equity Ratio 0.00
Volume 1,160,100
Avg Vol 804,888
Day's Range N/A - N/A
Shares Out 64.22M
Stochastic %K 37%
Beta 1.88
Analysts Sell
Price Target $13.50

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 21 at 1:21 AM
$ARVN oh I see you babyyyyy
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 19 at 5:51 PM
$ARVN @ $C oncology leadership summit, but didn't announce.
0 · Reply
DepthFollower
DepthFollower Feb. 18 at 9:15 AM
$ARVN Protein degradation platform with differentiated science; valuation tied to execution milestones.
0 · Reply
TwongStocks
TwongStocks Feb. 17 at 12:01 PM
$ARVN Earnings call confirmed. Feb 24 at 8:00am ET. https://www.globenewswire.com/news-release/2026/02/17/3239071/0/en/Arvinas-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-24-2026.html
0 · Reply
NewGuyHere94
NewGuyHere94 Feb. 13 at 8:45 PM
$ARVN buying more during this dip, sky is the limit with this don’t be scared !
0 · Reply
Regulator06
Regulator06 Feb. 13 at 1:55 PM
$ARVN Why promote internally? "Bringing in an outside CEO unfamiliar with PROTAC biology would require a long ramp-up period — risky at a time when the company is approaching major regulatory milestones. Translation: Scientific continuity likely mattered more than “fresh perspective.”
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 2:39 AM
$ARVN RSI: 40.71, MACD: 0.1789 Vol: 0.59, MA20: 13.00, MA50: 12.50 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Biodiad
Biodiad Feb. 13 at 1:23 AM
$ARVN Wow. MM took it down that much on so little volume.
0 · Reply
erpy
erpy Feb. 12 at 6:31 PM
$ARVN Added tons. Crazy drop for ridiculous reason. Ty for the cheapies. Retail never fails to surprise me.
1 · Reply
StocktwitsNews
StocktwitsNews Feb. 12 at 4:51 PM
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff $ARVN $VTI $IWM https://stocktwits.com/news/equity/markets/arvn-stock-drops-on-ceo-exit/cZRTqRDR4r8
0 · Reply
Latest News on ARVN
Arvinas to Participate in Upcoming Investor Conferences

Feb 23, 2026, 7:00 AM EST - 15 hours ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 17, 2026, 7:00 AM EST - 6 days ago

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Feb 12, 2026, 7:00 AM EST - 11 days ago

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Dec 6, 2025, 8:05 AM EST - 2 months ago

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 3 months ago

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Nov 24, 2025, 7:00 AM EST - 3 months ago

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 3:01 PM EST - 3 months ago

Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 3 months ago

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 4:00 PM EST - 4 months ago

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 4 months ago

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 24, 2025, 4:00 PM EDT - 4 months ago

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 22, 2025, 4:00 PM EDT - 4 months ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

Oct 20, 2025, 4:15 AM EDT - 4 months ago

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

PFE

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 13, 2025, 7:00 AM EDT - 4 months ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 5, 2025, 2:00 PM EDT - 5 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 1, 2025, 7:00 AM EDT - 5 months ago

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

Sep 17, 2025, 5:50 PM EDT - 5 months ago

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

PFE

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Sep 17, 2025, 4:30 PM EDT - 5 months ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 9, 2025, 10:12 AM EDT - 5 months ago

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Aug 8, 2025, 4:05 PM EDT - 7 months ago

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:24 PM EDT - 7 months ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 4:05 PM EDT - 7 months ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Jul 9, 2025, 7:00 AM EDT - 8 months ago

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Jun 13, 2025, 7:00 AM EDT - 9 months ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 6, 2025, 7:00 AM EDT - 9 months ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Jun 5, 2025, 8:28 AM EDT - 9 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

May 31, 2025, 8:06 AM EDT - 9 months ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 31, 2025, 8:00 AM EDT - 9 months ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas to Present at Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 9 months ago

Arvinas to Present at Jefferies Global Healthcare Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

May 16, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

May 15, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

May 14, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

May 13, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 10 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

May 9, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

May 8, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 21 at 1:21 AM
$ARVN oh I see you babyyyyy
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 19 at 5:51 PM
$ARVN @ $C oncology leadership summit, but didn't announce.
0 · Reply
DepthFollower
DepthFollower Feb. 18 at 9:15 AM
$ARVN Protein degradation platform with differentiated science; valuation tied to execution milestones.
0 · Reply
TwongStocks
TwongStocks Feb. 17 at 12:01 PM
$ARVN Earnings call confirmed. Feb 24 at 8:00am ET. https://www.globenewswire.com/news-release/2026/02/17/3239071/0/en/Arvinas-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-24-2026.html
0 · Reply
NewGuyHere94
NewGuyHere94 Feb. 13 at 8:45 PM
$ARVN buying more during this dip, sky is the limit with this don’t be scared !
0 · Reply
Regulator06
Regulator06 Feb. 13 at 1:55 PM
$ARVN Why promote internally? "Bringing in an outside CEO unfamiliar with PROTAC biology would require a long ramp-up period — risky at a time when the company is approaching major regulatory milestones. Translation: Scientific continuity likely mattered more than “fresh perspective.”
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 2:39 AM
$ARVN RSI: 40.71, MACD: 0.1789 Vol: 0.59, MA20: 13.00, MA50: 12.50 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Biodiad
Biodiad Feb. 13 at 1:23 AM
$ARVN Wow. MM took it down that much on so little volume.
0 · Reply
erpy
erpy Feb. 12 at 6:31 PM
$ARVN Added tons. Crazy drop for ridiculous reason. Ty for the cheapies. Retail never fails to surprise me.
1 · Reply
StocktwitsNews
StocktwitsNews Feb. 12 at 4:51 PM
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff $ARVN $VTI $IWM https://stocktwits.com/news/equity/markets/arvn-stock-drops-on-ceo-exit/cZRTqRDR4r8
0 · Reply
Regulator06
Regulator06 Feb. 12 at 4:41 PM
$ARVN bought some more thanks scared hands
2 · Reply
outlawinvestor1
outlawinvestor1 Feb. 12 at 4:04 PM
$ARVN market doesn’t like current team. bod should’ve hired externally.
1 · Reply
NewGuyHere94
NewGuyHere94 Feb. 12 at 3:02 PM
$ARVN panic sells, this is still such a goldmine and the new CEO has the credentials to only help excel PROTAC in the market, dips for more to jump in!
0 · Reply
BioSpecialOne
BioSpecialOne Feb. 12 at 2:46 PM
$ARVN wow pcs of s*it.... stupid retail panics like hell.....
0 · Reply
BioSpecialOne
BioSpecialOne Feb. 12 at 2:35 PM
$ARVN Drop is an Overreaction. Here is why the CEO change is BULLISH. The market sees "CEO Leaving" and panic sells (-6%). But look at the details: Continuity: Randy Teel isn't an outsider. He has been the CBO/Strategy Head since 2018. He knows the pipeline and the partners better than anyone. Smooth Transition: John Houston (outgoing CEO) isn't fleeing. He is staying as a Board Member and Consultant. This is a planned passing of the torch, not a "jump ship" scenario. Skillset: Moving from a scientific founder CEO to a Strategy/Business CEO (Teel is ex-McKinsey & Alexion) is exactly what a biotech needs as it matures towards commercialization. The PROTAC platform hasn't changed. The data hasn't changed. This is just a discount gifted by fearful algos.
2 · Reply
TwongStocks
TwongStocks Feb. 12 at 12:11 PM
$ARVN Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director https://www.globenewswire.com/news-release/2026/02/12/3237054/0/en/Arvinas-Announces-Appointment-of-Randy-Teel-Ph-D-as-President-Chief-Executive-Officer-and-Director.html
0 · Reply
Quantumup
Quantumup Feb. 10 at 9:17 PM
Stifel🏁 $OLMA Buy-$48 and said, We are initiating coverage of Olema Pharmaceuticals (OLMA) with a Buy rating and $48 Target Price. $AZN $LLY $RHHBY $ARVN BBOT Our thesis centers on lead asset palazestrant, a potential best-in-class oral SERD/CERAN. Its optimal pharmacology allows for sustained 24/7 estrogen receptor (ER) antagonism, which we believe is critical to preventing pro-oncogenic gene expression. We conservatively model peak sales of $3.1B in 2035 and stress that endocrine therapy in ER+/HER2- could be a $20B+ global market opportunity with plenty of room for many big players.
0 · Reply
biopuzzle
biopuzzle Feb. 10 at 5:48 PM
$ARVN any news? we are waiting 😉
0 · Reply
Greatguns
Greatguns Feb. 9 at 7:18 PM
$ARVN Arvinas, Inc. (ARVN) — Nightly Technical Analysis · Feb 6, 2026, 17:46 ET ARVN finished higher by 4.01% on Friday, February 6th, trading 0.7 times its typical volume. consolidation patterns formed: NR7, suggesting a potential continuation after price stabilization. Key support levels exist at 13.19, 12.91 & 12.69, with resistance at 13.69, 13.91 & 14.19.
0 · Reply
MoatMastery
MoatMastery Feb. 4 at 3:21 PM
$ARVN is a clinical-stage biotech developing protein degraders for cancer; its technology is novel but high-risk, with the pipeline still in early clinical development.
0 · Reply
Estimize
Estimize Feb. 4 at 11:01 AM
Wall St is expecting -0.79 EPS for $ARVN Q1 [Reporting 05/05 BMO] http://www.estimize.com/intro/arvn?chart=historical&metric_name=eps&utm_c
0 · Reply
Estimize
Estimize Feb. 2 at 12:00 PM
Wall St is expecting -0.51 EPS for $ARVN Q4 [Reporting 03/02 BMO] http://www.estimize.com/intro/arvn?chart=historical&metric_name=eps&utm_c
0 · Reply